<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126165</url>
  </required_header>
  <id_info>
    <org_study_id>17885</org_study_id>
    <secondary_id>17885</secondary_id>
    <nct_id>NCT00126165</nct_id>
  </id_info>
  <brief_title>Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer</brief_title>
  <official_title>A Phase I/II Study of Escalated-dose Short-course Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Calgary Health Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <brief_summary>
    <textblock>
      This study is aimed at providing further clinical evidence to support or refute the current
      understanding of biological sensitivity of prostate cancer to fractionated radiotherapy.
      Determining the morbidity and cancer control provided by a 4-week course of treatment will
      greatly influence future radiotherapy services for patients with localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is aimed at providing further clinical evidence to support or refute the current
      understanding of biological sensitivity of prostate cancer to fractionated radiotherapy.
      Determining the morbidity and cancer control provided by a 4-week course of treatment will
      greatly influence future radiotherapy services for patients with localized prostate cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rectal morbidity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage T1 and T2 prostate cancer

          -  Prostate specific antigen (PSA)&gt;=20 and Gleason score&lt;=6

          -  PSA&lt;=15 and Gleason score 7

          -  Signed informed consent

        Exclusion Criteria:

          -  No hip prosthesis, pins or screws

          -  No previous pelvic radiotherapy

          -  No inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jackson Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHS Cancer Control Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2005</study_first_submitted>
  <study_first_submitted_qc>August 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2005</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <keyword>prostate cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>hypofraction</keyword>
  <keyword>radiosensitivity</keyword>
  <keyword>image-guidance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

